Abstract
The retrospective analysis of clinical data of patients suffering from COVID-19 has indicated that statin therapy, used to lower plasma cholesterol levels, is associated with a better clinical outcome. We therefore investigated the effect of statins on SARS-CoV-2 infection and found that selective statins reduced SARS-CoV-2 cell entry and inhibited high and low pathogenic coronavirus infection in human cells. A retrospective study on hospitalized patients with COVID-19 implies that reduced high density lipoprotein levels, which are typically counteracted by statin therapy, are associated with aggravated disease outcome. These results suggest that statin therapy poses no additional risk to individuals exposed to SARS-CoV-2 and that some statins may have a mild beneficial effect on COVID-19 outcome. Placebo controlled trials are required to clarify the role of statins in COVID-19 infected patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Knut and Alice Wallenberg Foundation to G.G. Deutsche Forschungsgemeinschaft (DFG German Research Foundation) - Projektnummer 158989968 SFB 900 project C7 to G.G. and the DFG project GE 2145/3-2 to G.G. the German Academic Exchange Service (DAAD) to J.K. Infection Biology International PhD Program of Hannover Biomedical Research School to R.M. German Centre for Infection Research (DZIF) to A.P.G. and T.P. Helmholtz Alberta Initiative for Infectious Disease Research (HAI-IDR) and the Shandong University Helmholtz International Laboratory to T.P. This publication was supported by the European Virus Archive GLOBAL (EVA-GLOBAL) project that has received funding from the European Union Horizon 2020 research and innovation programme under grant agreement No 871029
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Hamburg State Chamber of Physicians (registration no.: WF-053/20)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
TCID50 data added to figure 1 and modifications in the text
Data Availability
No additional data reported or deposited
